Sai Parenterals Share Price

Total revenue of the Hyderabad-based company more than doubled to 198 crore in the quarter under review from 74 crore in the year-ago period

• Business Line
• 1 week 3 days ago

Pharmaceuticals company Sai Parenterals announced Q4FY26 & FY26 results Q4FY26 Financial Highlights: Total Income: Stood at Rs 200.81 crore, representing a growth of 169.97% compared to Q4FY25. Revenue: Stood at Rs 197.93 crore, with a growth of 166.65% on a YoYbasis. Gross Profit: Stood at Rs 76.51 crore, a growth of 374.3% compared to Q4FY25. EBITDA: Stood at Rs 28.97 crore, with a growth of 366.79% on a YoY basis. Profit After Tax (PAT): Stood at Rs 13.25 crore, with a growth of 736.04% on a YoY basis. EPS (INR): Stood at Rs 4.02, compared to Rs 0.59 in Q4FY25. FY26 Financial Highlights: Total Income: Stood at Rs 389.51 crore, a growth of 144.78% over FY25. Revenue: Stood at Rs 380.99 crore, with a growth of 140.37% on a YoY basis. Gross Profit: Stood at Rs 147.29 crore, a growth of 125.6% over FY25. EBITDA: Stood at Rs 47.21 crore, with a growth of 33.29% on a YoY basis. Profit After Tax (PAT): Stood at Rs 14.37 crore, with a growth of 45.52% on a YoY basis. EPS (INR): Stood at Rs 4.36, compared to Rs 3.71 in FY25. Business Highlights: Segment/Business Performance: The company witnessed a surge in CDMO revenue by over 250% YoY, supported by new long-term contracts. Growth in standalone performance was driven by deeper engagement with customers in export markets. Acquisition: The company acquired a 74.6% controlling stake in Australia-based Noumed Pharmaceuticals Pty Limited on November 12, 2025. This provides access to a portfolio of 451 dossiers and established customer relationships. Product Pipeline: Added 88 product dossiers in regulated and emerging markets in FY26, along with 5 dossiers with TGA Australia. Currently, 67 product dossiers are in the pipeline for commercialization in FY27. Capital Raise: Successfully completed an IPO in March 2026 with a primary fund raise of Rs 285 crore. Project Update: The company is executing a capex program including capacity expansion and EU-GMP upgradation at India facilities (Capex: Rs 118 crore), construction of a pharmaceutical plant in Australia (Capex: USD 53 million), and establishment of a new dedicated R&D; centre in India (Capex: Rs 18 crore). Anil KK, Managing Director, said: “We are proud to report an outstanding year of growth, led by a strong finish by SAl and its subsidiaries. This quarter marks the full consolidation of all its subsidiaries following its acquisition in November 2025, we are pleased to inform that Q4FY26 revenue crossing Rs 197.93 crore — a 166.65% jump YoY — and full year FY26 revenue reaching Rs 380.99 crore — a 140.37% jump YoY. More importantly, our profitability has improved dramatically, EBITDA grew 366.79% in Q4 and PAT surged 736% — clear evidence of the operating leverage in our model. For the full year, EBITDA grew 33.29% and PAT grew 45.52%. We remain committed to disciplined growth, margin improvement, and delivering sustained shareholder value in FY27 and beyond.” “Our business continues to be underpinned by a strong IP-led approach, with consistent additions of new dossiers across markets. Our COMO revenue have surged by over 250% YoY, supported by the signing of new long-term contracts that provide strong visibility for sustained growth in the coming years. We remain excited by the increasing scale of our operations and the opportunities emerging from our ongoing capex-led expansion. With ongoing capex of ~%440 crores expected to be completed in FY27, we believe the company is well positioned for the next phase of growth. We target to achieve 750 crore revenue for FY27 and EBITDA margins by to 17%. The outlook is underpinned by long-term supply agreements, the commercialization of new dossiers, strategic contribution from Noumed, Australia and sustained momentum across our exports and CDMO segments.” Result PDF

• Trendlyne
• 1 week 4 days ago

The 409-crore initial public offering of Sai Parenterals Ltd saw a subscription at 1.05 times, supported largely by institutional investors

• Business Line
• 2 months ago